Clinical Trials Logo
  1. Home
  2. Cardiogenic Shock
  3. NCT04144660
  4. Details
NCT04144660 Clinical Trial

"Treatment Use of ECMO In Pregnancy or Peripartum Patient."

Cardiogenic Shock Clinical Trial

Official title:
"Treatment Use of ECMO In Pregnancy or Peripartum Patient."

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04144660
Other study ID # PRO00036221
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 28, 2019
Est. completion date March 31, 2020

Study information
Verified date November 2020
Source Medical College of Wisconsin
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this study is to describe the use of ECMO (Extracorporeal Membrane Oxygenation) in the pregnant or peripartum patient.

Recruitment information / eligibility
Status Completed
Enrollment 5
Est. completion date March 31, 2020
Est. primary completion date March 31, 2020
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Female 2. Age 18 years or greater at the time of ECMO treatment. 3. Pregnant or within 6 months post-partum at the time of ECMO cannulation Exclusion Criteria: 1. No history of pregnancy. 2. No treatment with ECMO.

Study Design

Related Conditions & MeSH terms

Intervention

Device:
• Extracorporeal Membrane Oxygenation
Use of ECMO for circulatory / hemodynamic support of peripartum of pregnant patients who developed cardiogenic shock.

Locations
Country Name City State
United States Medical College of Wisconsin Milwaukee Wisconsin

Sponsors (2)
Lead Sponsor Collaborator
Sarah Thordsen Medical College of Wisconsin

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Clinical Outcome of Mother Describe clinical course of pregnant or recently postpartum patients with cardiogenic shock treated with ECMO, including the rate of neonate survival Time of diagnosis -Six Month Survival Rate
See also
  Status Clinical Trial Phase
Recruiting NCT03283995 - Hemodynamic Assessment in Cardiogenic Shock Regarding the Etiology
Active, not recruiting NCT04325035 - The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock Phase 2
Active, not recruiting NCT05100836 - SURPASS Impella 5.5 Study
Not yet recruiting NCT05106491 - Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients N/A
Completed NCT02301819 - ExtraCorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock N/A
Completed NCT01367743 - Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock Phase 4
Recruiting NCT05728359 - Genomic Determinants of Outcome in Cardiogenic Shock
Recruiting NCT05699005 - Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO Phase 1
Not yet recruiting NCT06338345 - Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients N/A
Completed NCT03436641 - Microcirculation in Cardiogenic Shock
Recruiting NCT03313687 - SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK
Recruiting NCT05506449 - The RECOVER IV Trial N/A
Completed NCT04548739 - Cerebral Autoregulation in Pediatric ECMO (ECMOX 2)
Recruiting NCT04141410 - Global Longitudinal Strain Assessment in Cardiogenic Shock During Sepsis
Not yet recruiting NCT05879276 - Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. Phase 3
Enrolling by invitation NCT05570864 - Score TO Predict SHOCK - STOP SHOCK
Completed NCT02591771 - Study of Multistep Pharmacological and Invasive Management for Cardiogenic Shock Phase 2
Terminated NCT02279979 - Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial N/A
Completed NCT01374867 - CardShock Study and Registry N/A
Recruiting NCT00093301 - Levosimendan Versus Dobutamine in Shock Patients Phase 2/Phase 3